Seres Therapeutics Inc (MCRB)
0.8485
+0.01
(+1.35%)
USD |
NASDAQ |
Oct 04, 16:00
0.8509
0.00 (0.00%)
After-Hours: 20:00
Seres Therapeutics SG&A Expense (Annual): 87.74M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 87.74M |
| December 31, 2022 | 79.69M |
| December 31, 2021 | 69.26M |
| December 31, 2020 | 30.78M |
| December 31, 2019 | 24.75M |
| December 31, 2018 | 32.60M |
| Date | Value |
|---|---|
| December 31, 2017 | 34.04M |
| December 31, 2016 | 32.62M |
| December 31, 2015 | 16.76M |
| December 31, 2014 | 4.364M |
| December 31, 2013 | 1.247M |
| December 31, 2012 | 0.956M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
24.75M
Minimum
2019
87.74M
Maximum
2023
58.44M
Average
69.26M
Median
2021
SG&A Expense (Annual) Benchmarks
| Chimerix Inc | 24.60M |
| Marinus Pharmaceuticals Inc | 61.15M |
| Jaguar Health Inc | 23.05M |
| PDS Biotechnology Corp | 15.28M |
| Mersana Therapeutics Inc | 59.54M |